Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection.

@article{Schneider1989DeterminationOT,
  title={Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection.},
  author={Werner Schneider and B Keller and P. H. Degen},
  journal={Journal of chromatography},
  year={1989},
  volume={488 1},
  pages={
          275-82
        }
}
View on PubMed
doi.org
10 Citations
Background Citations
1

10 Citations

Influence of food on the disposition of the monoamine oxidase‐A inhibitor brofaromine in healthy volunteers
TLDR
The slight effect of food on the bioavailability of brofaromine should be of little therapeutic consequence because of the observed wide inter‐subject variability of the plasma levels.
Role of cytochrome P4502D6 in the metabolism of brofaromine
TLDR
A role for the debrisoquine type of oxidation polymorphism in the O-demethylation and pharmacokinetic parameters of brofaromine and O-desmethyl-broFaromine in EM treated with quinidine is indicated.
The effect of the mao-a selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa
The new generation of monoamine oxidase inhibitors.
  • A. Cesura, A. Pletscher
  • Biology
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 1992
TLDR
In subjects with Parkinson's disease the MAO-B inhibitor L-deprenyl exerts a L-dopa-sparing effect, prolongs L- dopa action and seems to have a favorable influence regarding on-off disabilities.
Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
TLDR
Moclobemide administration leads to increased monoamine receptor stimulation, reversal of reserpine induced behavioral effects, selective depression of REM sleep, down regulation of beta-adrenoceptors and increases in plasma prolactin and growth hormone levels which suggest a neuroprotective role.
Influence of age, frailty and liver function on the pharmacokinetics of brofaromine
TLDR
Caffeine clearance, a simple, noninvasive test of CYP1A2 activity, is predictive of brofaromine clearance.
Monoamin-Oxidase-Hemmer
Die Monoamin-Oxidase (MAO, EC 1.4.2.4; Amin: Sauerstoff-Oxidoreduktase [desaminierend]) ist ein relativ unspezifisches mitochondriales Enzym. Es metabolisiert monoaminerge Neurotransmitter (wie…
Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.
TLDR
The selective and reversible MAO-A-I brofaromine and the SSRI fluvoxamine are equally effective in the treatment of PD and both compounds lead to a reduction in the number of panic attacks and a subsequent reduction in agoraphobic avoidance.
Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques
  • S. Mitsuhashi, T. Kojima, P. Hutson
  • Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques
  • 1992

References

Quantitative Determination of Brofaromin in Human Plasma after High Performance Liquid Chromatographic Separation
TLDR
The quantitative determination of a new antidepressant, the MAO‐inhibiting agent broFaromine, in human biological material is described and is suitable for pharmacokinetic studies after application of therapeutic doses of brofaromine.